


**Product Name** : SR-4835  
**Cat. No.** : PC-73102  
**CAS No.** : 2387704-62-1  
**Molecular Formula** : C<sub>21</sub>H<sub>20</sub>Cl<sub>2</sub>N<sub>10</sub>O  
**Molecular Weight** : 499.36  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** :



## Biological Activity

SR-4835 (SR4835) is a potent, highly selective dual inhibitor of CDK12 and CDK13 with IC<sub>50</sub> of 98 and 4.9 nM, respectively. SR-4835 is highly selective toward CDK12 and CDK13 when tested in a panel of over 450 kinases at 10 μM, including CDK4, CDK6, CDK9, GSK3A, and GSK3B.

SR-4835 blocks Ser2 phosphorylation on the CTD of RNA Pol II (EC<sub>50</sub>=100 nM), has no affinity to BRD4 and does not inhibit PARP activity.

SR-4835 blocked clonogenic growth and survival of MDA-MB-231 cells (IC<sub>50</sub>=15.5 nM) with increased potency over THZ531.

SR-4835 suppressed the expression of DNA damage repair proteins accompanied with increased DNA damage and cell death in tumor cells.

SR-4835 synergizes with DNA-damaging chemotherapeutics cisplatin and provokes TNBC cell death by downregulating DNA repair proteins.

SR-4835/Cisplatin combination provokes tumor regression in an orthotopic TNBC PDX model.

SR-4835/Irinotecan combination provokes regression in BRCA1-deficient PDX model.

## References

Quereda V, et al. Cancer Cell. 2019 Nov 11;36(5):545-558.e7.

Hopkins JL, et al. Cancer Cell. 2019 Nov 11;36(5):461-463.

Li Y, et al. Cancer Lett. 2020 Dec 28;495:12-21.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com